Discounted Cash Flow
Bridgebio Pharma, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | — | $-30.6m | $-41.0m | — | — |
| 2018 | — | $-130.7m (-327.8%) | $-138.8m (-239.0%) | — | — |
| 2019 | $40.6m | $-260.6m (-99.3%) | $-256.2m (-84.6%) | -642.5% | — |
| 2020 | $8.2m (-79.7%) | $-448.7m (-72.2%) | $-407.2m (-58.9%) | -5439.7% (-746.7%) | — |
| 2021 | $69.7m (745.1%) | $-562.5m (-25.4%) | $-511.2m (-25.5%) | -806.9% (85.2%) | — |
| 2022 | $77.6m (11.4%) | $-481.2m (14.5%) | $-424.3m (17.0%) | -619.7% (23.2%) | $-3.26 |
| 2023 | $9.3m (-88.0%) | $-643.2m (-33.7%) | $-529.0m (-24.7%) | -6913.9% (-1015.7%) | $-3.95 (-21.2%) |
| 2024 | $221.9m (2285.3%) | $-535.8m (16.7%) | $-521.7m (1.4%) | -241.4% (96.5%) | $-2.88 (27.1%) |
| 2025 | $502.1m (126.3%) | $-724.9m (-35.3%) | $-447.0m (14.3%) | -144.4% (40.2%) | $-3.78 (-31.2%) |
| 2026 | — | $-1.5m (99.8%) | — | — | $-0.01 (99.7%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.